Priyanka Arora, PhD

Gilead Sciences, Inc.
Foster City, California, United States

Disclosure information not submitted.

Presentation(s):

• 127 - No Clinically Significant Drug-Drug Interactions Between Lenacapavir and Hormonal Contraceptives in PURPOSE 1

  Monday, October 20, 2025
  12:20 PM - 12:25 PM US ET

• 128 - No Clinically Significant Drug–Drug Interactions with Co-administration of Feminizing or Masculinizing Hormone Therapy and Twice-yearly Lenacapavir PrEP in Gender-Diverse Persons

  Monday, October 20, 2025
  12:25 PM - 12:30 PM US ET

• 392 - Favorable Adherence and Safety of Twice-Yearly Subcutaneous Lenacapavir for PrEP Among PURPOSE 2 Participants Who Used Substances

  Tuesday, October 21, 2025
  2:09 PM - 2:21 PM US ET